Sam Brusco, Associate Editor04.17.23
Spine surgery device maker Aurora Spine has achieved initial surgeries using its SiLO TFX MIS sacroiliac joint fixation device were performed in the recent weeks. More than a dozen patients received the newly-FDA approved device, and all were successful.
SiLO TFX provides sacroiliac joint fusion foe sacroiliac joint disruptions and degenerative sacroiliitis. The system features a transfixing-cone, ilium screw, sacrum screw, and accompanying instrumentation. The implants are meant to transfix the sacrum and ilium for stability to achieve bony fusion.
According to the company, more than 30 million people suffer from lower back pain in the U.S., of which about 4.7 million are SI joint pain patients treated with non-surgical treatments. SiLO TFX was engineered for ease of implantation and uses a similar approach of therapeutic injections.
Trent Northcutt, Aurora’s president, CEO, and co-founder, told the press, "We are pleased with these initial surgeries using our SiLO TFX, which is a game changing device for the industry. These surgeries will enable us to enter into the next phase of commercialization, whereby we’ve begun to build inventory and kits to gear up for a full launch of the product by mid-year.”
Dr. Michael Stoffman, Neurosurgeon at the University at Buffalo Neurosurgery, said “SiLo TFX is a seamless, precise and efficient method to safely transfix the SI joint. I believe the SiLO TFX will result in superior clinical outcomes based on our positive biomechanical data with head to head testing of other transfixing SI joint devices.”
Dr. Steven Falowski, a Functional Neurosurgeon in Lancaster, Pa., commented, “The SiLO TFX marks the next chapter in treating patients safely and effectively with a minimally invasive option for sacroiliac joint fixation. It incorporates two well-known techniques of graft placement into the joint, and transfixation across the sacrum and ilium. The instrumentation allows for a smooth placement with a single small incision improving both the physician and patient experience."
SiLO TFX provides sacroiliac joint fusion foe sacroiliac joint disruptions and degenerative sacroiliitis. The system features a transfixing-cone, ilium screw, sacrum screw, and accompanying instrumentation. The implants are meant to transfix the sacrum and ilium for stability to achieve bony fusion.
According to the company, more than 30 million people suffer from lower back pain in the U.S., of which about 4.7 million are SI joint pain patients treated with non-surgical treatments. SiLO TFX was engineered for ease of implantation and uses a similar approach of therapeutic injections.
Trent Northcutt, Aurora’s president, CEO, and co-founder, told the press, "We are pleased with these initial surgeries using our SiLO TFX, which is a game changing device for the industry. These surgeries will enable us to enter into the next phase of commercialization, whereby we’ve begun to build inventory and kits to gear up for a full launch of the product by mid-year.”
Dr. Michael Stoffman, Neurosurgeon at the University at Buffalo Neurosurgery, said “SiLo TFX is a seamless, precise and efficient method to safely transfix the SI joint. I believe the SiLO TFX will result in superior clinical outcomes based on our positive biomechanical data with head to head testing of other transfixing SI joint devices.”
Dr. Steven Falowski, a Functional Neurosurgeon in Lancaster, Pa., commented, “The SiLO TFX marks the next chapter in treating patients safely and effectively with a minimally invasive option for sacroiliac joint fixation. It incorporates two well-known techniques of graft placement into the joint, and transfixation across the sacrum and ilium. The instrumentation allows for a smooth placement with a single small incision improving both the physician and patient experience."